ProMIS Neurosciences Announces Board and Executive Changes

Ticker: PMN · Form: 8-K · Filed: 2025-02-19T00:00:00.000Z

Sentiment: neutral

Topics: management-change, compensation

TL;DR

ProMIS Neurosciences shakes up its board and exec comp. Big changes coming?

AI Summary

ProMIS Neurosciences Inc. announced on February 14, 2025, changes in its board of directors and executive compensation arrangements. The filing details the departure of certain officers and directors, the election of new directors, and adjustments to compensatory arrangements for key personnel. These changes are effective as of February 14, 2025.

Why It Matters

Changes in board composition and executive compensation can signal shifts in company strategy, leadership stability, and future financial performance.

Risk Assessment

Risk Level: medium — Changes in leadership and compensation can indicate internal restructuring or strategic shifts, which carry inherent business risks.

Key Players & Entities

FAQ

What specific roles have changed for officers and directors?

The filing indicates the departure of certain officers and directors and the election of new directors, but does not specify the exact roles that have changed for each individual.

Are there any new executive appointments mentioned?

The filing mentions the appointment of certain officers, but does not provide specific names or titles of newly appointed executives.

What is the nature of the compensatory arrangements being adjusted?

The filing states that there are adjustments to compensatory arrangements for certain officers, but does not detail the specific changes to these arrangements.

When were these changes effective?

The changes reported in this 8-K filing were effective as of February 14, 2025.

Does this filing relate to any specific strategic initiatives?

While the filing details changes in leadership and compensation, it does not explicitly link these changes to specific strategic initiatives.

From the Filing

0001558370-25-001158.txt : 20250219 0001558370-25-001158.hdr.sgml : 20250219 20250219164532 ACCESSION NUMBER: 0001558370-25-001158 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20250214 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20250219 DATE AS OF CHANGE: 20250219 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ProMIS Neurosciences Inc. CENTRAL INDEX KEY: 0001374339 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: Z4 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41429 FILM NUMBER: 25641149 BUSINESS ADDRESS: STREET 1: SUITE 200, 1920 YONGE STREET CITY: TORONTO STATE: A6 ZIP: M4S 3E2 BUSINESS PHONE: 416-847-6898 MAIL ADDRESS: STREET 1: SUITE 200, 1920 YONGE STREET CITY: TORONTO STATE: A6 ZIP: M4S 3E2 FORMER COMPANY: FORMER CONFORMED NAME: AMORFIX LIFE SCIENCES LTD DATE OF NAME CHANGE: 20060831 8-K 1 pmn-20250214x8k.htm 8-K PROMIS NEUROSCIENCES INC._February 14, 2025 0001374339 false 0001374339 2025-02-14 2025-02-14 ​ ​ ​ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM  8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 14, 2025 PROMIS NEUROSCIENCES INC. (Exact name of registrant as specified in its charter) ​ ​ ​ ​ ​ ​ ​ Ontario, Canada ​ 001-41429 ​ 98-0647155 (State or other jurisdiction of incorporation) ​ (Commission File Number) ​ (IRS Employer Identification No.) ​ Suite 200 , 1920 Yonge Street , Toronto , Ontario , Canada      M4S 3E2 (Address of principal executive offices)   (Zip Code) ​ Registrant’s telephone number, including area code: ( 416 ) 847-6898 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: ​ Title of Each Class      Trading Symbol(s)      Name of Each Exchange on Which Registered Common Shares, no par value per share PMN The Nasdaq Capital Market ​ Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter) Emerging growth company ☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ ​ ​ ​ ​ Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On February 14, 2025, ProMIS Neurosciences Inc. (the “Company”) separated with Gavin T. Malenfant as Chief Operating Officer of the Company, effective as of February 14, 2025 (the “Separation”). In connection with the Separation, Mr.

View on Read The Filing